FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month extension of its collaboration with The Scripps Research Institute ("Scripps Research") and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research effective November 1, 2025, to advance the develop ...

Financial Performance - Xenetic Biosciences, Inc. reported financial results for the three months ended September 30, 2025[6]. - The company issued a press release on November 13, 2025, detailing its performance metrics[6]. - Specific financial figures and performance indicators are included in the press release, which is referenced as Exhibit 99.1[9]. - The report does not provide detailed numerical data or specific performance percentages in the available content[6][8]. - The company’s financial statements and additional exhibits are filed with the SEC[9]. Future Outlook - Forward-looking statements indicate expectations for future performance, subject to various risks and uncertainties[8]. - The company is subject to market factors and economic conditions that may impact its operations and results[8]. Product and Market Development - The company has not indicated any new product developments or market expansions in the provided documents[8]. - There is no mention of mergers or acquisitions in the current report[8]. Signatory Information - The report is signed by James Parslow, Interim Chief Executive Officer and Chief Financial Officer[13].

Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS Newswire / November 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the third quarter 2025. "We ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdic ...

Core Viewpoint - Xenetic Biosciences, Inc. has announced the pricing of an underwritten offering of common stock aimed at raising approximately $4.5 million to support its biopharmaceutical initiatives in immuno-oncology [1] Group 1: Offering Details - The company is offering 735,000 shares of common stock at a public price of $6.12 per share [1] - The gross proceeds from this offering are expected to be around $4.5 million before deducting underwriting discounts, commissions, and other estimated offering expenses [1] - All shares being offered are from Xenetic itself, indicating a primary offering rather than a secondary one [1]

Core Insights - Several companies have experienced significant stock price increases, attracting investor attention and market analysis [1] Company Summaries - **Xenetic Biosciences, Inc.**: Achieved a 142.31% increase in stock price, closing at $10.39, with a trading volume of 45,373,947. The company focuses on immuno-oncology technologies and has expanded its partnership with The Scripps Research Institute to advance CAR T-cell therapies [2] - **bioAffinity Technologies, Inc.**: Stock price rose by 108.60% to $0.48, with a volume of 29,850. The company specializes in non-invasive cancer diagnosis and treatment, showcasing the clinical value of its CyPath® Lung in detecting early-stage lung cancer [3] - **GigCapital7 Corp.**: Recorded an 89.43% increase in stock price, ending at $1.58. This SPAC is gaining interest due to its business combination with BigBear.ai, which has a pro forma enterprise value of $1.378 billion and aims to capitalize on AI/ML market opportunities [4] - **AlphaTON Capital Corp.**: Experienced an 85.48% rise in stock price to $10.35. The company is transitioning to a digital asset treasury model focused on Toncoin (TON) and is exploring the tokenization of single-indication economics for mesothelioma [5] - **Acurx Pharmaceuticals, Inc.**: Stock price increased by 74.36% to $7.48. The company is developing antibiotics for bacterial infections and received a positive opinion from the European Medicines Agency for its Pediatric Investigation Plan, positioning it for international Phase 3 clinical trials [6] Market Dynamics - The performances of these companies illustrate the dynamic nature of the stock market and the potential for significant returns, prompting investors and analysts to monitor future developments closely [7][8]

Core Insights - Xenetic Biosciences, Inc. (XBIO) shares experienced a significant increase of 123.41 percent, rising by $5.29 to reach $9.58, despite the absence of any apparent news driving this movement [1] - The stock is currently trading at $9.56, compared to a previous close of $4.29 on the Nasdaq, indicating a substantial price shift [1] - The shares opened at $11.72 and have fluctuated between $9.75 and $13.93 during the trading day, with trading volume surging to 42.3 million shares, significantly above the average of approximately 30,000 shares [1] Historical Performance - Over the past 52 weeks, Xenetic Biosciences shares have fluctuated between $2.20 and $13.93, with the recent spike pushing the stock to the upper end of its yearly range [2]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 150 points on Wednesday. The Dow rose by 0.08% to 46,642.55, the NASDAQ increased by 0.70% to 22,947.47, and the S&P 500 gained 0.35% to 6,738.32 [1] - Information technology shares saw a notable increase of 1.1% on Tuesday, while energy stocks declined by 0.9% [1] Mortgage Applications - The volume of mortgage applications in the U.S. decreased by 4.7% for the week ending October 3, following a more significant drop of 12.7% in the previous week [2][7] Commodity Prices - In commodity markets, oil prices rose by 0.9% to $62.26, gold increased by 1.3% to $4,058.00, silver was up by 1.9% to $48.395, and copper saw a slight rise of 0.1% to $5.0985 [4] European Markets - European shares showed positive performance, with the eurozone's STOXX 600 rising by 0.7%, Spain's IBEX 35 Index increasing by 0.8%, London's FTSE 100 up by 0.6%, Germany's DAX 40 gaining 0.8%, and France's CAC 40 rising by 0.9% [5] Asian Markets - Asian markets closed lower, with Japan's Nikkei 225 falling by 0.45%, Hong Kong's Hang Seng index down by 0.48%, and India's BSE Sensex declining by 0.19% [6] Stock Movements - Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged by 174% to $11.75, while Connexa Sports Technologies Inc. (NASDAQ: YYAI) saw a 102% increase to $0.3639. AlphaTON Capital Corp. (NASDAQ: ATON) shares rose by 81% to $10.08 [8] - Conversely, Galecto, Inc. (NASDAQ: GLTO) shares dropped by 42% to $10.48 after a significant jump of 383% on Tuesday. Zeta Network Group (NASDAQ: ZNB) shares fell by 41% to $2.00 following a $15 million registered direct offering at $1.00 per share. Envoy Medical, Inc. (NASDAQ: COCH) also experienced a decline of 38% to $0.9854 after announcing a $4 million registered direct offering at $1.33 per share [8]

[Form 8-K General Information](index=1&type=section&id=Form%208-K%20General%20Information) This section provides essential identification, contact information, and regulatory filing status for Xenetic Biosciences, Inc [Registrant Details](index=1&type=section&id=Registrant%20Details) This section provides the essential identification and contact information for Xenetic Biosciences, Inc., the entity filing this Form 8-K - Company Name: **Xenetic Biosciences, Inc.**[2](index=2&type=chunk) - Jurisdiction of Incorporation: **Nevada**[2](index=2&type=chunk) - Commission File Number: **001-37937**[2](index=2&type=chunk) - Principal Executive Offices Address: **945 Concord Street, Framingham, Massachusetts 01701**[2](index=2&type=chunk) - Registrant's Telephone Number: **(781) 778-7720**[2](index=2&type=chunk) [Filing Status and Provisions](index=1&type=section&id=Filing%20Status%20and%20Provisions) This part clarifies the specific regulatory provisions under which the Form 8-K is submitted and indicates the registrant's status regarding emerging growth company criteria - The Form 8-K is not intended to simultaneously satisfy filing obligations under **Rule 425, Rule 14a-12, Rule 14d-2(b), or Rule 13e-4(c)**[3](index=3&type=chunk) - The registrant is not an **'emerging growth company'** as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934[4](index=4&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02.%20Results%20of%20Operations%20and%20Financial%20Condition.) This section details the announcement of Xenetic Biosciences, Inc.'s financial results for the three months ended June 30, 2025 [Financial Results Announcement](index=2&type=section&id=Financial%20Results%20Announcement) Xenetic Biosciences, Inc. announced its financial results for the three months ended June 30, 2025, through a press release issued on August 13, 2025, which is incorporated by reference as Exhibit 99.1 - Date of Announcement: **August 13, 2025**[6](index=6&type=chunk) - Period Covered: **Three months ended June 30, 2025**[6](index=6&type=chunk) - Method of Announcement: **Press release (Exhibit 99.1** to this Current Report on Form 8-K)[6](index=6&type=chunk)[7](index=7&type=chunk) - The information in this Item 2.02, including Exhibit 99.1, is **'furnished' and not 'filed'** for purposes of Section 18 of the Securities Exchange Act of 1934, unless expressly set forth by specific reference in a filing[7](index=7&type=chunk) [Forward-Looking Statements](index=2&type=section&id=FORWARD-LOOKING%20STATEMENTS) This section provides a cautionary disclaimer for forward-looking statements, outlining their nature, risks, and update policy [Disclaimer and Risk Factors](index=2&type=section&id=Disclaimer%20and%20Risk%20Factors) This section serves as a cautionary note, indicating that the Form 8-K contains forward-looking statements subject to the safe harbor provisions, outlining their nature, associated risks, and the company's policy on updating such statements - Purpose: Intended to be subject to the **safe harbor provisions of the Private Securities Litigation Reform Act of 1995**[8](index=8&type=chunk) - Identification: Statements other than historical facts, identifiable by words such as **"expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates"**[8](index=8&type=chunk) - Actual activities, performance, achievements, or results may differ materially due to factors described in the **"Risk Factors" section of the Company's SEC reports** (Form 10-K, 10-Q, 8-K), general market/economic conditions, public health issues, geopolitical events, competitive product development, regulations, manufacturing issues, patent positions, litigation, and shareholder activism[8](index=8&type=chunk) - The Company does not undertake any obligation to update forward-looking statements, except as required by law[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01.%20Financial%20Statements%20and%20Exhibits.) This section provides a comprehensive list of all documents filed as exhibits to this Form 8-K [List of Exhibits](index=2&type=section&id=List%20of%20Exhibits) This section provides a detailed list of all documents filed as exhibits to this Form 8-K, including the press release announcing financial results and the interactive data file - **Exhibit 99.1**: Press Release dated **August 13, 2025**, pertaining to the financial results of the Company for the **three months ended June 30, 2025**[9](index=9&type=chunk) - **Exhibit 104**: Cover Page Interactive Data File (embedded within the Inline XBRL document)[9](index=9&type=chunk) [Signatures](index=3&type=section&id=SIGNATURES) This section formally concludes the Form 8-K with the signature of an authorized officer [Authorized Signatory](index=3&type=section&id=Authorized%20Signatory) This section formally concludes the Form 8-K with the signature of an authorized officer, confirming the report's submission on behalf of Xenetic Biosciences, Inc - Registrant: **XENETIC BIOSCIENCES, INC.**[12](index=12&type=chunk) - Signatory: **James Parslow**[12](index=12&type=chunk) - Title: **Interim Chief Executive Officer & Chief Financial Officer**[12](index=12&type=chunk) - Date: **August 13, 2025**[12](index=12&type=chunk)

Group 1: Earnings Performance - Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the Zacks Consensus Estimate of a loss of $0.64, and improved from a loss of $0.83 per share a year ago, representing an earnings surprise of +29.69% [1] - The company posted revenues of $0.59 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 7.81%, and down from $0.73 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Group 2: Stock Performance and Outlook - Xenetic Biosciences shares have lost about 30.8% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.65 on $0.72 million in revenues, and -$2.56 on $2.7 million in revenues for the current fiscal year [7] Group 3: Industry Context - The Medical - Drugs industry, to which Xenetic Biosciences belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]